Exploration of claims-based utilization measures for detecting potential nonmedical use of prescription drugs

Journal of Managed Care Pharmacy

Volumn 20, Issue 6, 2014, Pages 639-646

  Birt, Julie ^a   Johnston, Joseph ^a   Nelson, David ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODYDRAMOL; HYDROCODONE BITARTRATE PLUS PARACETAMOL; ILLICIT DRUG; OXYCODONE PLUS PARACETAMOL; PRESCRIPTION DRUG; ALPRAZOLAM; AMPHETAMINE PLUS DEXAMPHETAMINE; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLONAZEPAM; COCODAMOL; HYDROCODONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; LEVOTHYROXINE SODIUM; LISDEXAMFETAMINE; LORAZEPAM; METHYLPHENIDATE; MODAFINIL; MORPHINE; OPIATE; OXYCODONE; ROSUVASTATIN; SIMVASTATIN; TRAMADOL; ZOLPIDEM TARTRATE;

ADULT; ARTICLE; DRUG ABUSE; DRUG UTILIZATION; FEMALE; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; UNITED STATES; ALGORITHM; COHORT ANALYSIS; DRUG UTILIZATION REVIEW; MEDICATION COMPLIANCE; MIDDLE AGED; TOTAL QUALITY MANAGEMENT; DATA MINING; DRUG MISUSE; DRUG USE; INSURANCE; RISK FACTOR; SUBSTANCE-RELATED DISORDERS; TIME;

ALGORITHMS; DATA MINING; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRESCRIPTION DRUG MISUSE; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; UNITED STATES;

EID: 84901192877     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.6.639     Document Type: Article

References (12)

1. National Institute on Drug Abuse. DrugFacts: prescription and over the counter medications. Revised May 2013. Available at: http://www.drugabuse.gov/publications/drugfacts/prescription-over-counter-medications. Accessed April 25, 2014.
2. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;13(5):401-35.
3. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain. 2011;27(3):194-202.
4. Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder. Pharmacoeconomics. 2011;29(7):621-35.
5. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469-79.
6. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36-44.
7. Hallas J, Nissen A. Individualized drug utilization statistics. Analysing a population's drug use from the perspective of the individual users. Eur J Clin Pharmacol. 1994;47(4):367-72.
8. Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol. 2007;64(2):210-18.
9. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4): 850-56.
10. Pohl GM, Van Brunt DL, Ye W, Stoops WW, Johnston JA. A retrospective claims analysis of combination therapy in the treatment of adult attentiondeficit/ hyperactivity disorder (ADHD). BMC Health Serv Res. 2009;9:95.
11. Hallas J, Støvring H. Templates for individual-level prescription data. Basic Clin Pharmacol Toxicol. 2006;98(3):260-65.
12. U.S. Justice Department. Drug Enforcement Administration. Oxycontin diversion and abuse. October 2003. Available at: https://www.ncjrs.gov/App/ publications/abstract.aspx?ID=203602. Accessed May 12, 2014.